3 results about "Lung abscess" patented technology

The invention relates to a therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess. [Problem] The present invention relates to a safer and more effective therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess, said agent containing, as an active ingredient, 7-[(3S, 4S)-3-{(cyclopropylamino) methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

The present invention is a therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess. [Problem] The present invention relates to a safer and more effective therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess, said agent containing, as an active ingredient, 7-[(3S, 4S)-3-{(cyclopropylamino) methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.